AbbVie Inc (ABBV)vsCastle Biosciences Inc (CSTL)
ABBV
AbbVie Inc
$234.89
+0.06%
HEALTHCARE · Cap: $391.50B
CSTL
Castle Biosciences Inc
$21.38
-2.73%
HEALTHCARE · Cap: $627.83M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 18381% more annual revenue ($62.82B vs $339.92M). ABBV leads profitability with a 5.8% profit margin vs -3.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CSTL
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$234.89
$88.67 premium
Margin of Safety
+58.2%
Fair Value
$77.42
Current Price
$21.38
$56.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 4.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while CSTL is a turnaround play — different risk/reward profiles.
CSTL carries more volatility with a beta of 1.02 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. CSTL offers better value entry with a 58.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a leading diagnostics company dedicated to improving patient care through cutting-edge gene-expression profiling tests, specifically in the realm of skin cancer, with its flagship product, DecisionDx®-Melanoma. This innovative solution provides crucial insights into patient risk stratification, thus facilitating informed treatment decisions in melanoma management. With a steadfast commitment to precision medicine and a robust research and development framework, Castle Biosciences is strategically positioned to expand its portfolio and address pivotal clinical needs. By focusing on the complexities of oncology, the company aims to enhance clinical outcomes while driving significant value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?